Search Results - "JANSAT, Josep M"

Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 cm2: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis by DuBois, Janet, Jones, Terry M., Lee, Mark S., Falqués, Meritxell, Kiyasova, Vera, Jiménez, Gemma, Otero, Raquel, Jansat, Josep‐M., Aubets, Jordi, Forconi, Rion James

“…Tirbanibulin ointment 1% is approved in the United States and Europe for the treatment of actinic keratosis with demonstrated efficacy, safety, and…”
Get full text

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial by Schmid, Karin, MD, Pascual, Silvia, MSc, Gil, Esther Garcia, MD, Ortiz, Stephan, RPh, PhD, Jansat, Josep M., PhD

“…Abstract Background: Aclidinium bromide is an inhaled, long-acting muscarinic antagonist currently in development for the treatment of chronic obstructive…”
Get full text

Identification of the Human Liver Enzymes Involved in the Metabolism of the Antimigraine Agent Almotriptan by SALVA, Miquel, JANSAT, Josep M, MARTINEZ-TOBED, Antonio, PALACIOS, Jose M

“…Almotriptan is a novel highly selective 5-hydroxytryptamine 1B/1D agonist developed for the acute oral treatment of migraine. The in vitro metabolism of…”
Get full text

Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm 2 : A Phase 1 Maximal-Use Trial in Patients with Actinic Keratosis by DuBois, Janet, Jones, Terry M, Lee, Mark S, Falqués, Meritxell, Kiyasova, Vera, Jiménez, Gemma, Otero, Raquel, Jansat, Josep-M, Aubets, Jordi, Forconi, Rion James

“…Tirbanibulin ointment 1% is approved in the United States and Europe for the treatment of actinic keratosis with demonstrated efficacy, safety, and…”
Get full text

Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long-Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants by Jansat, Josep M., Lamarca, Rosa, de Miquel, Gonzalo, Schrödter, Andreas, Miletzki, Barbara, Gurniak, Matthias

“…Systemic exposure to anticholinergics used for chronic obstructive pulmonary disease (COPD) may lead to side effects. This study assessed safety, tolerability,…”
Get full text

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants by Ortiz, Stephan, Flach, Stephen, Caracta, Cynthia, Gil, Esther Garcia, Jansat, Josep M.

“…Aclidinium bromide is a long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease treatment. This 2-part, phase I study…”
Get full text

Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum by Timmerman, Philip, Luedtke, Silke, van Amsterdam, Peter, Brudny-Kloeppel, Margarete, Lausecker, Berthold, Fischmann, Stephanie, Globig, Susanne, Sennbro, Carl-Johan, Jansat, Josep M, Mulder, Hans, Thomas, Elizabeth, Knutsson, Magnus, Kasel, Dirk, White, Stephen A, Kall, Morten Anders, Mokrzycki-Issartel, Nathalie, Freisleben, Achim, Romero, Fernando, Andersen, Michael Pilgård, Knebel, Norbert, de Zwart, Marcel, Laakso, Sirpa, Hucker, Richard S, Schmidt, Dietmar, Gordon, Ben, Abbott, Richard, Boulanger, Pierre

“…Following intensive discussions, review, alignment of procedures and multiple surveys among their member companies, the European Bioanalysis Forum (EBF) is…”
Get more information

Mass balance and metabolism of aclidinium bromide following intravenous administration of [14C]-aclidinium bromide in healthy subjects by Ortiz, Stephan, Flach, Stephen, Ho, John, Li, Fanying, Caracta, Cynthia F., Gil, Esther Garcia, Jansat, Josep M.

“…ABSTRACT Aclidinium bromide is a novel, inhaled long‐acting muscarinic antagonist with low systemic activity developed for the treatment of COPD. It is an…”
Get full text

Effect of MAO‐A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans by Fleishaker, Joseph C., Ryan, Kristi K., Jansat, Josep M., Carel, Barabara J., Bell, David J. A., Burke, Moira T., Azie, Nkechi E.

“…Aims  To assess the effect of a reversible MAO‐A inhibitor, moclobemide, on the single‐dose pharmacokinetics of almotriptan and assess the clinical…”
Get full text

Absolute Bioavailability, Pharmacokinetics, and Urinary Excretion of the Novel Antimigraine Agent Almotriptan in Healthy Male Volunteers by Jansat, Josep M., Costa, Joan, Salvà, Pau, Fernandez, Francisco J., Martinez-Tobed, Antonio

“…Absolute bioavailability, pharmacokinetics, and urinary excretion of almotriptan, a novel 5‐HT1B/1D receptor agonist, were studied in 18 healthy males…”
Get full text

Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs by Puigdemont, A, Queralt, M, Jansat, J M, Martinez-Tobed, A

“…The pharmacokinetics and pharmacodynamics of ebastine at single oral doses of 10 and 20 mg were studied in six healthy beagle dogs. Plasma concentrations of…”
Get more information

Almotriptan, a New Anti‐Migraine Agent: A Review by Gras, Jordi, Llenas, Jesús, Jansat, Josep M., Jáuregui, José, Cabarrocas, Xavier, Palacios, José M.

“…ABSTRACT Almotriptan is a new anti‐migraine agent with nanomolar affinity for human 5‐HT1B, 5‐HT1D, and 5‐HT1F receptors, weak affinity for 5‐HT1A and 5‐HT7…”
Get full text